Moderna Surges 177% Overnight on Melanoma Vaccine Trial Success; ETF Premium Triggers Trading Halts
According to Jin10 data, Moderna surged 177% overnight on August 20 following the company's announcement with Merck of successful results for a melanoma skin cancer vaccine in a large-scale trial.
Meanwhile, multiple China-listed ETFs experienced significant premiums on August 20, triggering
MRNA-7.58%
GateNews·08-20 01:16



